Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
FX-909 by Flare Therapeutics for Solid Tumor: Likelihood of Approval
FX-909 is under clinical development by Flare Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Data Insights
FX-909 by Flare Therapeutics for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
FX-909 is under clinical development by Flare Therapeutics and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According...